PACS

Pacs Group Inc

Add to Watchlist

Advanced Chart

11.690

+0.26(2.275%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.990

Open

11.540

VWAP

11.73

Vol

379.50K

Mkt Cap

1.81B

Low

11.540

Amount

4.45M

EV/EBITDA(TTM)

Total Shares

155.18M

2.28B

EV/OCF(TTM)

P/S(TTM)

PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. The Company is focused on delivering skilled nursing care through a portfolio of independently operated facilities. It also provides its independently operated facilities with a comprehensive suite of technology, support, and back-office services. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after they have been discharged from the hospital. This ecosystem ranges from higher acuity, higher-cost settings, such as long-term acute care hospitals and inpatient rehabilitation facilities, to lower acuity, lower-cost settings, such as assisted living facilities, and home health. The Company’s independent subsidiaries operate about 314 post-acute care and senior living facilities across 17 states, serving over 30,000 patients daily.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

1.10B

+17.46%

0.420

+23.24%

Estimates Revision

The market is revising Downward the revenue expectations for PACS Group, Inc. (PACS) for FY2024, with the revenue forecasts being adjusted by -1.39% over the past three months. During the same period, the stock price has changed by 21.39%.

Revenue Estimates for FY2024

Revise Downward

-1.39%

In Past 3 Month

EPS Estimates for FY2024

Revise Downward

-4.19%

In Past 3 Month

Stock Price

Go Up

+21.39%

In Past 3 Month

1 Analyst Rating

173.74% Upside

Wall Street analysts forecast PACS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACS is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

173.74% Upside

Current: 11.690

Low

32.00

Averages

32.00

High

32.00

173.74% Upside

Current: 11.690

Low

32.00

Averages

32.00

High

32.00

Macquarie

Tao Qiu

Buy

Maintains

$42 → $24

2025-01-06

Reason

Macquarie

Tao Qiu

Price Target

$42 → $24

2025-01-06

Maintains

Buy

Reason

Truist Securities

David Macdonald

Strong Buy

Maintains

$46 → $32

2025-01-06

Reason

Truist Securities

David Macdonald

Price Target

$46 → $32

2025-01-06

Maintains

Strong Buy

Reason

JP Morgan

Lisa Gill

Buy

Hold

Downgrades

$18

2024-12-17

Reason

JP Morgan

Lisa Gill

Price Target

$18

2024-12-17

Downgrades

Buy

Hold

Reason

JPMorgan downgraded Pacs Group to Neutral from Overweight with an $18 price target. The firm moved to the sidelines after the company postponed its Q3 earnings and said it received civil investigative demands from the federal government regarding its reimbursement and referral practices. This has created a prolonged overhang on the stock, the analyst tells investors in a research note.

Stephens & Co.

Scott Fidel

Buy

Maintains

$48 → $31

2024-11-18

Reason

Stephens & Co.

Scott Fidel

Price Target

$48 → $31

2024-11-18

Maintains

Buy

Reason

Stephens lowered the firm's price target on Pacs Group to $31 from $48 and keeps an Overweight rating on the shares after the company provided notification of late filing with the SEC for its most recent 10-Q and amended its existing credit agreement, providing an extension to the covenant pertaining to delivery of unaudited financial statements. The firm maintains its 2024-2026 adjusted EBITDA estimates, but cites reduced visibility due to the internal audit committee investigation currently underway and an ongoing federal inquiry for its lowered target, pending the Q3 10-Q release.

JP Morgan

Lisa Gill

Buy

Initiates

$40

2024-11-06

Reason

JP Morgan

Lisa Gill

Price Target

$40

2024-11-06

Initiates

Buy

Reason

Truist Securities

David Macdonald

Strong Buy

Maintains

$44 → $46

2024-10-14

Reason

Truist Securities

David Macdonald

Price Target

$44 → $46

2024-10-14

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pacs Group Inc (PACS.N) is 7.28, compared to its 5-year average forward P/E of 13.39. For a more detailed relative valuation and DCF analysis to assess Pacs Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

13.39

Current PE

7.28

Overvalued PE

19.97

Undervalued PE

6.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

15.11

Current EV/EBITDA

10.61

Overvalued EV/EBITDA

19.62

Undervalued EV/EBITDA

10.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

0.82

Current PS

0.42

Overvalued PS

1.24

Undervalued PS

0.40